Professor Liu Min's team: Countdown to eliminating hepatitis B in 2030! The global trend of hepatitis B-related liver disease burden is revealed

In 2016, the World Health Organization (WHO) set the goal

Recently, a study published by Professor Liu Min of the School of Public Health of Peking University in Hepatol Int (Impact Factor 9.

According to the 2019 Global Burden of Disease (GBD 2019) study, data on annual new cases and age-standardized incidence (ASIR) of HBV infection-related liver diseases were collected between 1990 and 2019, and trends

Table 1 SDI values and UHCI by country and region in 2019

(Swipe up and down to see more)

1.

Globally, the number of new cases of HBV-related liver disease in 2019 was 80.

For the disease spectrum of HBV-related liver disease, the new cases of acute hepatitis decreased by 4.

Through the analysis of 5 SDI areas, new cases of HBV-related liver disease in 1990-2019 decreased in medium (18.
86%), moderate-high (24.
77%) and high SDI areas (18.
68%), but increased
in low (53.
04%) and low-medium SDI areas (11.
79%).

ASIR declined in all SDI regions, with the largest decline in the medium-high SDI region (EAPC=-2.
20; 95% CI -2.
48, -1.
92).

Figure 1 Compare ASIR for HBV-associated liver disease in different SDI regions from 1990 to 2019

2.
Trends in HBV-related burden of cirrhosis and other chronic liver diseases

Global ASIR for HBV-associated cirrhosis and other chronic liver diseases decreased by an average of 0.
89% per year (95% CI 0.
76%, 1.
02%)
between 1990 and 2019.

An analysis of 5 SDI regions showed a decrease in ASIR in the medium, middle-high, and high SDI regions, but an average annual increase of 0.
13% (95% CI 0.
04%, 0.
22%) in low-SDI regions and an average annual increase of 0.
24% (95% CI 0.
04%, 0.
34%)
in low-middle SDI regions.

Figure 2 Compare ASIR of HBV-associated cirrhosis and other chronic liver diseases in different SDI regions from 1990 to 2019

3.
Trends in HBV-related liver cancer burden

From 1990 to 2019, the ASIR of HBV-associated liver cancers worldwide decreased by an average of 3.
10% per year (95% CI 2.
53%, 3.
66%)
.

Through the analysis of 5 SDI regions, the ASIR of HBV-associated liver cancer decreased in low, low-middle, moderate-high SDI regions, but increased by an average annual increase of 0.
91% (95% CI 0.
37%, 1.
46%)
in high SDI regions.

Figure 3 Compare ASIR for HBV-associated liver cancer in different SDI regions from 1990 to 2019

From 1990 to 2019, the GLOBAL ASIR of HBV-associated liver disease showed a gradual downward trend, but the trend of changes in its disease spectrum varied
from region to region.

An increase in ASIR for HBV-associated cirrhosis and other chronic liver diseases was observed in low, low-to-moderate SDI areas, and an increasing trend in ASIR for HBV-associated liver cancer was observed in high SDI regions
.

Thus, in order to achieve the goal of eliminating viral hepatitis as a public health threat globally by 2030, eliminating hepatitis B requires attention not only to developing regions, but also to developed regions
.

Public health progress can be made if governments have a strong will and budget to improve the availability and affordability of hepatitis B vaccines and treatments in less developed regions and to monitor for hepatocellular carcinoma in developed regions
.

Professor Liu Min

• Professor of the Department of Epidemiology and Health Statistics, School of Public Health, Peking University, and doctoral supervisor

• Deputy Director of the Center for AIDS Prevention and Prevention, School of Public Health, Peking University

• Member of the National Expert Group of the National Health Commission on Novel Coronavirus Pneumonia

• Vice President of the Second National Council of the Maternal and Child Health Research Association

• Chairman of the Rehabilitation Big Data Working Committee of the Chinese Rehabilitation Medicine Association

• Vice Chairman of the Health Management Professional Committee of Beijing Preventive Medicine Association

• Member of the Expert Steering Committee of the Fifth Council of Beijing Community Health Association

• Member of the Public Health Expert Committee of Beijing Medical Doctor Association

• Expert of Beijing Municipal Expert Group on Continuing Medical Education

• He has undertaken more than 50 scientific research projects funded by the National Natural Science Foundation of China, the Surface Project, the Ministry of Science and Technology 863 Project, the Science and Technology Innovation 2030 Major Project, the Infectious Disease Major Project, the National Key Research and Development Program, the National "Eleventh Five-Year Plan" and "Twelfth Five-Year Plan" Major Science and Technology Support Program Project, the Capital Health Development Scientific Research Project, the World Bank Health Ministry Loan Project, the National Health Commission, the China Disabled Persons' Federation, the World Health Organization, the United Nations Women, and the Beijing Municipal Science and Technology Commission
  。
  

• He has edited and participated in the compilation of more than 50 textbooks and books, and published more than 270 papers, including internationally renowned journals
  such as Lancet Global Health, Lancet Infectious Disease, Gut, Bull World Health Organ and so on.
  
  

• He has won 1 second prize of the Chinese Medical Science and Technology Award, 1 first prize and 2 second prizes of the Beijing Science and Technology Award, 1 first prize and 2 third prizes of the Science and Technology Award of the Chinese Preventive Medicine Association, 2 first prizes of the National Maternal and Child Health Science and Technology Award, and many other awards
  such as the Advanced Collective (Collective Leader) of the National Science and Technology System to Combat the New Crown Pneumonia Epidemic.
  
  

References: Cao G, Jing W, Liu J, Liu M.
Countdown on hepatitis B elimination by 2030: the global burden of liver disease related to hepatitis B and association with socioeconomic status.
Hepatol Int.
2022 Sep 1.
doi: 10.
1007/s12072-022-10410-y.